About Index Trending news
Analyze
Pricing
Exelixis

Exelixis

Exelixis

At Exelixis, our vision is to build a global biopharmaceutical company providing new treatment options to cancer patients.
I work here Suggest edits
More info

Elsewhere

Also headquartered in San Francisco

Twitter Twitter Uber Uber Instagram Instagram Lyft Lyft Airbnb Airbnb Salesforce Salesforce Reddit Reddit Fitbit Fitbit TechCrunch TechCrunch Slack Slack

Companies in the same industry

Capnia, Inc. Capnia, Inc. Health eFilings Health eFilings DNAsimple DNAsimple New Wave Foods New Wave Foods Benchmark Holdings plc Benchmark Holdings plc Lucerno Dynamics Lucerno Dynamics Sartorius Sartorius Frontida BioPharm, Inc. Frontida BioPharm, Inc. Immune-Onc Therapeutics Immune-Onc Therapeutics accuRx accuRx

Alexa global traffic share

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview
Add info
Employees

Team size

200+
Locations
HQ
San Francisco, United States
Headquarters
The Motley Fool

Exelixis, Inc. Setting New Standard of Care

Exelixis
Exelixis
The Motley Fool

Exelixis, Inc. Gets Some ASCO Love

Health
Exelixis
Exelixis
The Motley Fool

Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May

Exelixis
Exelixis
The Motley Fool

These 2 Billionaires Are Dumping Exelixis' Stock. Should You?

Stock markets
Exelixis
Exelixis
The Motley Fool

This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales

Exelixis
Exelixis
The Motley Fool

Exelixis, Inc. Prepares for Blastoff

Health Announcements
Exelixis
Exelixis
The Motley Fool

2 Big Reasons Why Shares of Exelixis, Inc. Soared 15% in April

Health Stock markets Earnings
Exelixis
Exelixis
The Motley Fool

Better Buy: Exelixis, Inc. vs. Roche

Roche
Roche
Exelixis
Exelixis
The Motley Fool

Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin!

Health
Exelixis
Exelixis
The Motley Fool

Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot

Stock markets Health
Exelixis
Exelixis
The Motley Fool

Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb

Bristol-Myers Squibb
Bristol-Myers Squibb
Exelixis
Exelixis
The Motley Fool

Why Exelixis' Stock Dropped 10% on Tuesday

Exelixis
Exelixis
The Motley Fool

Exelixis, Inc. Partnering Before Approval

Health
Exelixis
Exelixis
The Motley Fool

Exelixis Inc. Stock Was Throttled in February -- Here's Why

Exelixis
Exelixis
Xconomy

On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug

Health Earnings
Exelixis
Exelixis
The Motley Fool

Emotional Investing Deflates Exelixis, Inc. in January

Exelixis
Exelixis
The Motley Fool

Why Exelixis, Inc. Rocketed Higher on Friday

Stock markets Health
Exelixis
Exelixis
The Motley Fool

Exelixis, Inc. Nearly Quadrupled in 2015 -- Here's Why --

Exelixis
Exelixis
The Motley Fool

Why Exelixis, Inc. Is Trading Higher Today --

Stock markets Health
Exelixis
Exelixis
The Motley Fool

The FDA Approves Exelixis, Inc's New Cancer Drug --

Health
Exelixis
Exelixis